CYP7A1 and atherosclerosis: Using another animal model of dyslipemia, namely the apoE KO mouse, here again we show that prolonged treatment with T-0681 reduces late atherosclerosis development, which was associated with a decrease in the circulating levels of pro-atherogenic apoB-containing lipoproteins and increased hepatic expression of ABCG5/G8 and CYP7A1.